Its innovative multi-dose capacity minimizes the need for frequent refills, enabling farmers to vaccinate large herds efficiently and seamlessly. Combined with its high-pressure ejection system and self-cleaning mechanism, Velocity X reduces downtime, improves workflow, and ensures consistent delivery—saving time, labor, and resources during large-scale vaccination efforts.
MULTIPLE
DOSES
Multiple points of injection significantly enhance mRNA uptake by ensuring broader and more even distribution of the vaccine within the tissue. Traditional single-point injections can create localized delivery, limiting how effectively the mRNA reaches cells.
SPECIALIZED
NEEDLE
Higher pressure in the ejection process enhances mRNA uptake by driving the vaccine deeper into the tissue and improving cellular access. Traditional low-pressure injections often result in surface-level dispersion, limiting the vaccine's penetration and effectiveness.
PRESSURE
PRECISION
Velocity X features a self-cleaning mechanism that utilizes high-pressure ejection to flush the system with sterilizing agents like isopropyl alcohol or ethanol.
SELF CLEANING
ACCELERATOR MECHANISM
VelocityX
1
Specialized Needle
Multiple Points of Injection
Multiple points of injection significantly enhance mRNA uptake by ensuring broader and more even distribution of the vaccine within the tissue. Traditional single-point injections can create localized delivery, limiting how effectively the mRNA reaches cells.
2
Pressure Precision
High Pressure Mechanism
Higher pressure in the ejection process enhances mRNA uptake by driving the vaccine deeper into the tissue and improving cellular access. Traditional low-pressure injections often result in surface-level dispersion, limiting the vaccine's penetration and effectiveness.
3
Self Sterilizing
Avoiding Cross Contamination
VelocityX features a self-cleaning mechanism that utilizes high-pressure ejection to flush the system with sterilizing agents like isopropyl alcohol or ethanol.
4
Fully Loaded
Increasing the Speed
Its innovative multi-dose capacity minimizes the need for frequent refills, enabling farmers to vaccinate large herds efficiently and seamlessly. Combined with its high-pressure ejection system and self-cleaning mechanism, VelocityX reduces downtime, improves workflow, and ensures consistent delivery—saving time, labor, and resources during large-scale vaccination efforts.
VelocityX
The Vaccine Accelerator
VelocityX is a vaccine delivery accelerator equipped with a specialized needle and high-pressure mechanism designed for rapid, precise, and efficient administration. By significantly reducing injection time and minimizing vaccine wastage, it enables large-scale immunization with fewer resources. Its streamlined design ensures safety, improves patient comfort, and optimizes manpower, making it ideal for mass vaccination campaigns.
Strategy
VelocityX: The steps ahead
VETERINARY APPLICATIONS
VelocityX will be recognized as a transformative technology for veterinary vaccine development and deployment. VelocityX will empower veterinarians, farmers, and researchers with a reliable tool to combat diseases, safeguard food security, and protect biodiversity.
FASTER AND SMARTER
VACCINATIONS
With our patent-pending technology, VelocityX revolutionizes the speed and efficacy of mRNA vaccine development. By streamlining production and delivery, it ensures rapid and effective responses to outbreaks, protecting animal health and advancing global efforts to prevent and control diseases.
GLOBAL PARTNERSHIPS
Collaborating with leading medical device producers, VelocityX leverages their expertise and infrastructure to accelerate research and development. These partnerships ensure feasibility by streamlining prototyping, testing, and manufacturing processes.
VelocityX Timeline
NOW
Patent Pending
Our innovative mRNA accelerator is patent pending, securing intellectual property rights as we prepare for the next steps.
2025-2026
R&D
Beginning in 2025, resources will be allocated to design, develop, and test the first working prototype. Rigorous lab trials will ensure the device meets high standards of efficiency, reliability, and safety.
2026-2027
Market Launch
VelocityX is aimed to enter mass production by 2026 and be distributed in bulk to veterinary suppliers globally. This phase ensures the device reaches end-users quickly, providing immediate benefits in animal health management.
2027-2030
Real World
Intel
Field use of VelocityX will be closely monitored to evaluate its impact and further validate its effectiveness. Ongoing research will refine the technology and document its positive effects across diverse applications.
2030
FDA
By 2030, VelocityX will aim to reach FDA approval for start of clinical research in humans, cementing its role as a transformative tool in mRNA vaccine development and veterinary medicine. This milestone will mark a new era in combating animal diseases globally.
VelocityX
VelocityX Explained
Meet the Team
With expertise in manufacturing, finance, and STEM research, our founders bring a unique blend of industry insight and scientific innovation to the development of VelocityX, a next-generation vaccination accelerator. Their experience in full-value chain manufacturing, quality control, and global research initiatives ensures a strong foundation for advancing cutting-edge biomedical solutions.
CEO
VΙVΙΑΝΝΕ JΑΚΟΒSSΟΝ
With a background in STEM, she is driven by a strong interest for environmental sustainability. She has been involved in and driving research projects in Singapore, Sweden, and Germany, and is also the founder of VelocityX.
Chairman of the Board
MATS JΑΚΟΒSSΟΝ
Mats is a technology and financial entrepreneur with a background in chemistry, manufacturing, trading and real estate. Specialising in manufacture financing and trading full value chains with Mitsui Trading, manufacture control at Bureau Veritas and asset valuation at American Appraisals.
Business Strategist
ANNA GRANGER
Anna started her career in Finance at Global Asset Management and Merrill Lynch in London. Her interest in content, design and sustainable living led her to establish and lead multiple businesses in these areas focusing on innovation and ensuring that businesses make a positive impact on society.
Marketing
ANDI GRANGER
A senior creative and marketing executive Andrew has worked as a Creative Director for leading media organisations including Sky and the BBC along with founding and running his own design studio in London. In addition to marketing and design, Andrew is passionate about sustainability and is co-owner of lifestyle and interior businesses that prioritise environmentally responsible practices.